Abstract
Introduction
For economic evaluations alongside clinical trials, the National Institute for Health and Care Excellence (NICE) Technical Support Document for survival analysis offers a process guide demonstrating how modeling survival can be undertaken in a transparent and consistent manner [1] . The guide reviews different methods that are applicable in situations when baseline patient characteristics that influence the survival outcome are evenly distributed across the treatment arms. Although this is often the case, e.g., if the full population data of a randomized controlled trial (RCT) is used as randomization and stratification ensures balance, conducting adjusted analyses might be helpful to assess the robustness of the primary analysis [2] . In addition, reimbursement agencies often try to optimize the use of new therapies in particular post hoc subgroups and/ or positions where imbalances in prognostic and predictive factors are present. In such cases, adjusted survival should be generated; however, it might be challenging to determine the appropriate survival model and make survival predictions for the study population based on the fitted model.
If baseline characteristics are balanced and proportional hazards are accepted, a typical modeling approach to predict survival for the active arm is to fit a parametric model to the survival data of the control arm and apply a hazard ratio (HR) estimated separately with a Cox proportional hazards model to this baseline [3] . This approach may lead to biased survival predictions and overstated uncertainty in the cost-effectiveness analysis because the size of the treatment effect and the uncertainty associated with that is assumed independent of the shape and uncertainty of the baseline hazard. Instead, fitting a suitable parametric model to the entire dataset with treatment group included as a covariate is more appropriate [3] . In case imbalances in patient characteristics are present, similarly to unadjusted survival prediction, two approaches are typically considered: fitting a parametric survival model to the control arm data and applying an adjusted HR to this baseline; or fitting a model to the entire dataset with prognostic and predictive factors included as covariates. Whichever approach is taken, the assumptions of the applied survival model (e.g., proportional hazards) should be satisfied for all covariates or any violations (e.g., non-proportionality) must be modeled explicitly.
Another challenge is that even if the assumptions of the survival model are satisfied or the violations are ignored, the way in which predictions with multiple regression models are made for the study population is not straightforward. In practical applications, two different methods are used: the mean of covariates and the corrected group prognosis methods [4, 5] . With the mean of covariates method, the mean value of each covariate is applied and survival is predicted for a patient with average baseline characteristics, whereas with the corrected group prognosis method survival is predicted for each patient and the average of the individual predictions is calculated.
An alternative approach to obtaining covariate-adjusted survival estimates is to use propensity score weighting or matching that corrects for imbalances in prognostic and predictive factors as a first step [6] [7] [8] , and to fit a parametric model with treatment group included as the only covariate to the weighted or matched data as a second step. In economic evaluations, propensity score methods are commonly employed to adjust for selection bias when non-randomized observational data are used [9] ; however, it is rarely applied to correct for imbalance in patient characteristics when RCT data are available.
To date, no formal guidance has been developed regarding how covariate-adjusted survival estimates should be prepared for economic evaluations. Therefore, our study aimed to assess and compare different adjusted survival modeling approaches. The alternative approaches are illustrated by application to overall survival (OS) data in an RCT in multiple myeloma.
Methods

Data
Survival data and baseline patient characteristics were used from the phase III ENDEAVOR RCT that compared treatment with carfilzomib plus dexamethasone (Cd) versus bortezomib plus dexamethasone (Vd) in patients with relapsed/refractory multiple myeloma (n = 464 for Cd, n = 465 for Vd) [10] . In the trial, Cd was associated with statistically significant OS benefit over Vd [11] . For the present study, data from bortezomib-naïve patients who had received one prior therapy (n = 136 for Cd, n = 131 for Vd) were used (data cut-off in March 2016). Cd was compared with Vd in the subgroup to reflect NICE guidance on the use of bortezomib [12] and consequent treatment patterns observed in the real world in England and Wales [13] 
Covariate Selection
Since differences in factors that are strongly related to the outcome can cause bias in the treatment effect estimate [14] , variables that were considered to be predictive and prognostic factors for OS were identified. The variable selection process was based on the opinion of two leading UK-based hemato-oncologists highly experienced in the treatment of multiple myeloma. Specifically, the clinicians were provided with a broad list of variables, guided by subject-matter expertise and a review of the existing literature [15] [16] [17] [18] [19] , from which they had to select those that they considered to be prognostic and/or predictive factors. The selected covariates reflected tumor stage, disease burden, and treatment history, and were generally consistent with robustly validated prognostic markers currently used in stratifying patients into different risk groups [20, 21] . Overall, the covariate selection strategy took account of current knowledge regarding prognostic factors in relapsed/refractory multiple myeloma. In contrast, with the large number of baseline variables recorded in the ENDEAVOR trial, a purely statistical approach to variable selection may have resulted in the inclusion of variables with no clinical relevance [22, 23] . The clinicians identified 13 risk factors, 1 of which two were used to construct the subgroup of interest (number of prior treatments, prior bortezomib exposure) and one (cytogenetic risk status) was not included due to the high proportion of missing data (16%). Imputing missing data was explored and is presented in the Electronic Supplementary Material.
Since some of the clinician-identified risk factors are correlated (e.g., international staging system group with β 2 -microglobulin level, age with stem cell transplantation), the treatment group and the clinician-identified covariates were entered in a Cox proportional hazards model, and an automated stepwise variable selection procedure was applied to obtain a more parsimonious set of covariates [24] . Although retaining covariates with overlapping information does not bias results if the underlying model is correctly specified, it increases the standard error for the outcomes of interest (i.e., HR and mean OS). Therefore, the approach allowing for a combination of expert opinion and data-driven modeling to select prognostic variables for the survival prediction model was considered optimal for the purpose of the study. The variable selection strategy was implemented in R using the stepAIC package, which minimized the Akaike Information Criterion by removing or adding variables [25] . Besides this base-case covariate selection method, two alternative sets of covariates were explored for sensitivity analyses: all clinician-identified covariates; and covariates that were retained by applying the least absolute shrinkage and selection operator (LASSO) variable selection method [22, 26] .
Covariate-Adjusted Survival Extrapolation Methods
Weighted Data Approach
With the approach based on propensity score weighting [6] [7] [8] , covariate-adjusted survival was predicted in two steps. In the first step, propensity score estimates were created that were used to re-weight the patient-level data and, as a result, to correct for baseline imbalance in covariates.
To estimate the individual propensity scores (i.e., the inverse of the probability that a patient receives his/her assigned treatment) [7] , a logistic regression model was applied in which the treatment indicator was defined as the dependent variable and the covariates identified in the stepwise selection Cox model were used as independent variables. Using these covariates was considered to be justified because it has been demonstrated that variables that are unrelated to the exposure but related to the outcome should be included in the propensity score model [27, 28] . By virtue of the randomized design of the ENDEAVOR trial, covariates were naturally unrelated to the treatment received, and by the design of the covariate selection method, covariates were related to the outcome. The same procedure was applied in sensitivity analyses where variables that were retained with the other covariate selection methods were used for the weighting.
In the second step, using the weighted dataset, the proportional hazards assumption for the treatment indicator was assessed. Since the log-cumulative hazard plots, the Schoenfeld residuals plot, and the Therneau and Grambsch test result indicated no violation of the proportional hazards assumption (see details in the Electronic Supplementary Material), parametric survival models were fitted to the two arms of the weighted patient-level data, including the treatment group indicator as the only covariate. Besides the models assuming proportional hazards (i.e., Weibull, Gompertz, exponential, generalized gamma), the log-logistic, and lognormal models were also assessed. The most appropriate parametric distribution was selected based on the statistical fit of the survival models and based on the clinical plausibility of the extrapolations.
Visual inspection of the modeled versus the weighted Kaplan-Meier curves, and the goodness-of-fit statistics suggested that the survival models were mostly similar; hence, the clinical plausibility of the long-term extrapolations had significant impact in determining the most appropriate parametric function [29] . Ultimately, this was achieved through the use of external data and clinical expert opinion. In particular, comparison of parametric extrapolations with published long-term OS data from the DOXIL-MMY-3001 trial [30] suggested that the Weibull function provides the most plausible OS extrapolations among those assessed [31] . In addition, feedback from 12 UK consultant hematologists provided validation of the Weibull function [31] . The Electronic Supplementary Material provides details on the assessment of survival models, the model selection, and clinical expert validation process.
Mean of Covariates and Corrected Group Prognosis Approach
With the mean of covariates and the corrected group prognosis approaches, covariate-adjusted survival was estimated with a Weibull regression model that was fitted to the unweighted data and included the same covariates as those used for propensity score weighting in the base case. While the mean of covariates and corrected group prognosis approaches used the same parametric survival model, they differed in the way in which patient-level information were utilized for the covariates. Specifically, with the mean of covariates approach survival was estimated for a patient with average baseline characteristics, whereas with the corrected group prognosis approach survival was estimated by averaging the individual predictions for each patient given the patient's baseline covariate values. To calculate the average baseline characteristics and to predict individual survival for Cd and Vd, patients from both treatment arms were pooled. This approach ensured that survival predictions for both arms were obtained for an average patient and that these survival estimates were comparable with those obtained by the weighted data approach.
Adjusted Hazard Ratio Approach
Lastly, with the adjusted HR approach, a Weibull model was fitted to the survival data of the Vd arm, to which a HR estimated separately in a multiple Cox proportional hazards model was applied to predict survival for the Cd arm. Similarly to the other approaches, the multiple Cox proportional hazards model adjusted for imbalances in covariates that were identified in the stepwise selection Cox model. The proportional hazards assumption was assessed and accepted for all covariates.
Analysis
HRs, restricted mean survival estimates at 36 months, and the mean OS were estimated for the treatments using the four modeling approaches. OS was extrapolated for a follow-up of 30 years, which allowed for an appropriate lifetime horizon considering the median age at baseline was 65 years [32] . The mean OS values were derived by calculating the area under the predicted survival curves. 95% CIs around the mean estimates were generated by non-parametric bootstrapping (n = 1000) [33] . All analyses were performed using the R statistical software [34] .
Results
Results of Covariate Selection
Of the ten clinician-identified prognostic/predictive factors that were subject to the automated variable selection procedure in a Cox proportional hazards model, six covariates were retained (see Table 1 ). With the LASSO variable selection procedure, almost all clinician-identified covariates were retained; only two covariates were excluded (see Table 2 ).
Results of Matching
Prior to weighting, large differences existed between the treatment groups with respect to ECOG (Eastern Cooperative Oncology Group) performance status (Cd: 58.5% vs. Vd: 41.7% of patients with score ≥ 1) and history of stem cell transplantation (Cd: 41.5% vs. Vd: 52.8%). After weighting, these differences were virtually eliminated (Cd: 49.9% vs. Vd: 50.0% for ECOG score, and Cd: 47.2% vs. Vd: 47.3% for stem cell transplantation). For other covariates, baseline differences were smaller but re-weighting the patient population decreased these imbalances even further. By design, re-weighting did not change the total sample size; however, it decreased the sample size for Cd to 130.5 (− 2.6%) and increased the sample size for Vd to 131.5 (+ 2.8%). Baseline patient characteristics before and after weighting together with the standardized mean differences are presented in Table 1 . Distribution plots and summary statistics for the inverse probability weights are provided in the Electronic Supplementary Material. Compared to the base case, applying other covariate selection methods had only a small impact on the covariate balance (see Electronic Supplementary Material).
Survival Outcomes
The adjusted HRs estimated based on the different approaches are presented in Table 2 . The HR using the weighted data approach was estimated to be 0.62 (95% CI 0.38-1.02), indicating a lower risk of death for Cd patients than for Vd patients. Different sets of covariates used for adjustment in the alternative propensity score models had minor impact on the HR. Similar HRs were obtained with the multiple Weibull model and with the multiple Cox proportional hazards model as well. Figure 1 presents the Kaplan-Meier OS curves estimated using the original unweighted data and using the weighted data in the base case. Larger differences between the treatment arms were observed after weighting. Figure 1 also presents the Weibull survival model that was fitted to the weighted data. The Weibull model appeared to have a good fit to the weighted Kaplan-Meier curves and provided clinically plausible long-term extrapolations. Figure 2 compares the OS predictions based on all the four modeling approaches for Vd (Fig. 2a) and for Cd (Fig. 2b) . For both treatments, predictions based on the mean of covariates approach appeared to be skewed because the short-term survival of a patient with average characteristics was markedly longer than that indicated by the average of the patient-specific survival estimates, as derived by the corrected group prognosis approach. In contrast, predictions based on the corrected group prognosis approach appeared to fit the data well in the short run; however, long-term predictions indicated more than 10% of the Vd population to be alive after 30 years, which was considered to be clinically implausible. OS predictions based on the adjusted HR approach were anchored to the Vd arm survival data and were similar to those based on the weighted data approach. Table 2 presents the absolute mean survival estimates for Cd and Vd, as well as the difference between the treatment arms, for each of the various modeling approaches. The restricted mean OS at 36 months estimated by the weighted data approach was 2.60 years (95% CI 2.48-2.73) for Cd and 2.40 years (95% CI 2.24-2.54) for Vd, which gave a difference of 0.20 years (95% CI 0.02-0.40). The different adjusted survival prediction approaches resulted in broadly similar mean restricted OS estimates, except for the mean of covariates approach which yielded larger estimates.
The mean OS estimated by the weighted data approach was 6.85 years (95% CI 4.62-10.70) for Cd, 4.68 years (95% CI 3.46-6.74) for Vd, and 2.17 years (95% CI 0.18-5.06) for the difference in the mean OS. Higher mean OS estimates but similar mean OS differences were predicted with the mean of covariates and the corrected group prognosis approaches. Estimates obtained by the adjusted HR approach were similar to those of the weighted data approach; however, the uncertainty around these estimates was substantially larger: the mean OS was 6.75 years (95% CI 3.93-13.19) for Cd, 4.72 years (95% CI 3.25-8.49) for Vd, and 2.03 years (95% CI − 0.17 to 6.19) for the difference in these.
Discussion
The present study assessed four alternative covariateadjusted survival modeling approaches which were applied to a subgroup of the ENDEAVOR RCT in multiple myeloma. The weighted data approach involved using propensity score weighting to correct for imbalances in baseline characteristics and fitting a Weibull model to the two arms of the balanced data with treatment group included as the only covariate. The regression-based approaches encompassed the mean of covariates and the corrected group prognosis methods for which a Weibull regression model including prognostic and predictive covariates was used, and a method based on applying an adjusted HR to the baseline Vd risk estimated with a Weibull model to obtain survival estimates for the Cd arm.
Of the various covariate-adjusted survival modeling approaches, the one based on weighted data was considered to provide the most suitable method for several reasons. Firstly, this approach does not require the proportional hazard assumption to be satisfied for all the covariates. Instead, it uses propensity scores to correct for the pretreatment imbalances in observed baseline characteristics. Since the weighted dataset is balanced with respect to prognostic and predictive factors across the treatment groups, any difference in survival can be assumed to be due to treatment and there is no need for further adjustment. Consequently, the modeling methods recommended in the NICE Decision Support Unit (DSU) guide for survival analysis can be applied directly [1] . Secondly, the approach allows visual comparison of the weighted Kaplan-Meier curves to the modeled curves, which is a key step in determining the most plausible survival model used for health economic modeling; in particular, that it allows an assessment and estimation of the treatment effect over time. Thirdly, fitting a survival model to weighted data in an actual cost-effectiveness analysis requires the same steps as using an unadjusted survival model; therefore, it can be considered simple and transparent. Finally, propensity score techniques can be advantageous compared with regression-based adjustment techniques when the number of covariates is not excessively large because propensity scores summarize all baseline covariates into a single score and therefore are an important dimension reduction tool for evaluating the treatment effect [35] . This characteristic may be particularly preferred over regression-based adjustment methods when several covariates are considered and the non-linear and/or time-dependent effect of these covariates potentially need to be modeled individually. An inherent limitation of using a multiple parametric regression model (Weibull in the present case) for survival predictions is that its assumptions (i.e., proportional hazards) have to be satisfied for all the covariates included or any non-proportionality must be modeled explicitly. While in the current application the proportional hazard assumption was satisfied for all baseline characteristics, in other applications this might not be the case; thus, the validity of the survival extrapolations may be questionable and/or the survival model can become complex. Another limitation associated with using multiple parametric regression models for survival predictions is that assumptions should be satisfied for all covariates (not only for the treatment effect) for the period beyond the trial. Such a requirement adds further uncertainty to the extrapolations.
A limitation specific to the mean of covariates approach is that it can yield skewed survival estimates because the survival expectation of a patient with average baseline characteristics might be different from the average of the patientspecific survival expectations [36] . Survival predictions in the present study appeared to suffer from such bias. Another limitation of the mean of covariates approach is that covariate values between 0 and 1 are assigned to binary variables. Although the most prevalent value could also be taken, if the mean is used, the value cannot be interpreted on an individual level. On the other hand, the main benefit of using this approach is that it is transparent and easy to implement for probabilistic sensitivity analyses. The advantage of the corrected group prognosis approach over the mean of covariates approach is that it takes into account individual heterogeneity for the survival predictions. However, its implementation when probabilistic sensitivity analyses are conducted involves either sharing confidential patient-level data within the cost-effectiveness model, necessary to automate the simulations, or entering externally generated survival profiles as hard input parameters. While the first approach might not be feasible, the second approach is not transparent. Lastly, the corrected group prognosis method yielded implausible long-term survival predictions in the present application. This may be caused by some patients that had baseline characteristics very different from the average characteristics, and for whom the long-term survival could not be estimated robustly. Additionally, different patients might have a different individual death risk pattern over time that is not captured by the survival model. These situations may also occur in other applications where heterogeneous patient populations are modeled.
The adjusted HR approach suffers from the same limitations as the multiple regression-based modeling approaches because proportional hazards must be assumed for each covariate, or any non-proportionality should be modeled explicitly. Besides, although its implementation in a health economic model is transparent, as stated in the NICE DSU survival analysis guideline, the approach overstates uncertainty for the probabilistic sensitivity analysis as the correlation between the baseline risk parameters and the treatment effect parameter is not considered [1] . Finally, in contrast to the previous three approaches, which estimate survival for the average patient of the subgroup, the adjusted HR approach anchors survival predictions to the average control arm patient. Since imbalances in the treatment and control conditions are present, patients receiving control arm treatment cannot be labeled as average subgroup patients.
A summary of the advantages and disadvantages of the assessed covariate-adjusted survival modeling approaches is presented in Table 3 .
The present study concluded that, of the assessed approaches, the one based on weighted data was the most suitable for use in economic evaluations. Since proportional hazards were accepted for Cd versus Vd, Weibull models that were fitted jointly to the two treatment arms were used. Although situations when the proportional hazards are not accepted were not assessed, there is no theoretical reason to believe that the weighted data approach should not be preferred in these cases as well. Based on the NICE DSU guidance on survival analysis, in situations when the proportional hazards are not accepted, parametric models that do not assume proportional hazards can be applied, individual models can be fitted to each treatment arm separately, or alternative modeling methods such as time-varying HRs and piecewise modeling can be considered [1] . Once balance in the baseline characteristics is achieved via weighting, the principles described in the NICE survival analysis guideline can readily be applied using the weighted data.
Another limitation of the present study is that the covariate distributions across the treatment arms after matching was not assessed formally. It has been recommended that balance between the moments of a covariate distribution rather than simply for the mean should be measured [37] . For the current study, however, only the means of the baseline characteristics were compared, as the optimal covariate balance was beyond the scope of this analysis. Nonetheless, similarity of the HRs and the mean OS estimates across the various propensity score models indicated that different specifications had limited impact on the results. In an ideal situation, the propensity score model should be modified if covariate balance is not achieved, and the resulting covariate balance be re-checked until balance is obtained [38] . To achieve an optimal covariate balance, matching methods other than propensity score weighting might be considered. For instance, genetic matching, which algorithmically optimizes covariate balance, has been shown to outperform propensity score matching in certain situations [39] . To our knowledge, approaches based on propensity score methods to correct for baseline imbalances in covariates have been rarely used in reimbursement submissions in oncology. Based on a targeted review of health technology appraisals performed by NICE, two submissions have been identified that employed propensity score matching for the estimation of covariate-adjusted survival. In one of these economic evaluations, propensity score analysis was performed to balance measured patient characteristics in a historical cohort and the study population of the active treatment [40] , whereas in the other submission it was used to conduct an adjusted indirect comparison between two separate trials with the aim of reducing bias in the efficacy analysis [41] . In both cases, propensity score matching was applied in a non-randomized setting, leaving some risk of bias due to unmeasured confounding. When propensity score matching is applied alongside an RCT, as it was in the present case, such risk of bias can be considered negligible.
Conclusion
Economic evaluations in oncology aim to provide unbiased estimates of health economic outcomes and are commonly built using survival data from RCTs. If imbalances in baseline characteristics are present, failure to adjust for the pretreatment imbalances may result in skewed survival predictions that have little value for decision-making. To date, no formal guidance has been developed regarding how such adjustments should be made. The present study assessed various covariate-adjusted survival modeling methods and concluded that the approach based on weighted data provides a flexible and robust method for health economic modeling purposes. The conclusions of this study applied to an RCT in multiple myeloma may be generalizable to other settings, although in different applications matching methods other than propensity score weighting might need to be considered.
